BHVN vs. CRNX, RARE, PBH, HCM, BHC, INSM, CBAY, XENE, IDYA, and FOLD
Should you be buying Biohaven stock or one of its competitors? The main competitors of Biohaven include Crinetics Pharmaceuticals (CRNX), Ultragenyx Pharmaceutical (RARE), Prestige Consumer Healthcare (PBH), HUTCHMED (HCM), Bausch Health Companies (BHC), Insmed (INSM), CymaBay Therapeutics (CBAY), Xenon Pharmaceuticals (XENE), IDEAYA Biosciences (IDYA), and Amicus Therapeutics (FOLD). These companies are all part of the "pharmaceutical preparations" industry.
Crinetics Pharmaceuticals (NASDAQ:CRNX) and Biohaven (NYSE:BHVN) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, community ranking, media sentiment, earnings, analyst recommendations, risk, profitability and valuation.
Crinetics Pharmaceuticals presently has a consensus price target of $54.00, indicating a potential upside of 16.15%. Biohaven has a consensus price target of $52.13, indicating a potential upside of 27.23%. Given Crinetics Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Biohaven is more favorable than Crinetics Pharmaceuticals.
Crinetics Pharmaceuticals has higher earnings, but lower revenue than Biohaven. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.
Crinetics Pharmaceuticals has a beta of 0.63, meaning that its share price is 37% less volatile than the S&P 500. Comparatively, Biohaven has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500.
Biohaven received 235 more outperform votes than Crinetics Pharmaceuticals when rated by MarketBeat users. However, 66.18% of users gave Crinetics Pharmaceuticals an outperform vote while only 65.37% of users gave Biohaven an outperform vote.
98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. Comparatively, 88.8% of Biohaven shares are held by institutional investors. 7.0% of Crinetics Pharmaceuticals shares are held by insiders. Comparatively, 16.0% of Biohaven shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Biohaven has a net margin of 0.00% compared to Biohaven's net margin of -4,223.27%. Biohaven's return on equity of -52.93% beat Crinetics Pharmaceuticals' return on equity.
In the previous week, Crinetics Pharmaceuticals had 2 more articles in the media than Biohaven. MarketBeat recorded 4 mentions for Crinetics Pharmaceuticals and 2 mentions for Biohaven. Biohaven's average media sentiment score of 0.93 beat Crinetics Pharmaceuticals' score of 0.50 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the media.
Summary
Crinetics Pharmaceuticals beats Biohaven on 10 of the 18 factors compared between the two stocks.
Get Biohaven News Delivered to You Automatically
Sign up to receive the latest news and ratings for BHVN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BHVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Biohaven Competitors List
Related Companies and Tools
